| • |
Completed $30 million private placement with potential total proceeds of up to $85 million upon full cash exercise of warrants, to build-out the U.S. commercial team needed to support revenue growth following recent availability of the
FemaSeed® fertility portfolio to OB/GYNs, and to fund the FemBloc® pivotal trial to support U.S. approval.
|
| • |
Highlights for the FemaSeed Fertility Portfolio (Diagnostics: FemVue® for her and SpermVueTM for him; first-step treatment: FemaSeed and FemSperm®):
|
| o |
Announced a partnership with both UNC Health and Minnesota Women’s Care to introduce the entire portfolio across its OB/GYN practice locations.
|
| o |
Announced a partnership with CapexMD to expand patient access through financing solutions and SandsRx Pharmacy for medications to support treatment timing.
|
| • |
Highlights for FemBloc Permanent Birth Control:
|
| o |
Issuance of patents in the U.S. and key international markets that expand intellectual property protection for the blended polymer component.
|
| o |
Received FDA approval of the modular premarket approval (PMA) submission approach.
|
| o |
Announced the number of actively enrolling sites in the FINALE trial to support U.S. approval doubled to twelve sites.
|
| • |
Sales in the U.S.
increased slightly to $347,039 in 2026 from $336,594 in 2025, while overall sales decreased by $324,797, or 44.5%, to $404,597 from $729,394. The overall decline was anticipated and reflects the timing of international FemBloc orders,
consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed.
|
| • |
Research and development expenses increased by $560,905, or 40.6%, to $1,942,927 in 2026 compared to $1,382,022 in 2025, primarily reflecting the transition of development products into inventory to support
commercialization during 2025, and increased clinical costs and compensation costs during 2026.
|
| • |
Net loss was $4,564,815, or ($0.53) per basic and diluted share attributable to common stockholders, for the quarter ended September 30, 2026, compared to a net loss of $4,194,821, or ($2.05) per basic and diluted share attributable to
common stockholders, for the quarter ended September 30, 2025.
|
| • |
Sales in the U.S.
increased slightly to $1,038,997 in 2026 from $1,015,168 in 2025, while overall sales decreased by $318,613, or 21.5%, to $1,161,313 from $1,479,926. The overall decline was anticipated and reflects the timing of international FemBloc
orders, consistent with distributors’ customary bulk-ordering practices. Distributors are utilizing existing inventory to support FemBloc post-market studies, with reorders expected after those studies are completed.
|
| • |
Research and development expenses decreased by $565,717, or 9.8%, to $5,199,206 in 2026 compared to $5,764,923 in 2025, primarily reflecting lower compensation costs, regulatory fees and outside consultant
costs, partially offset by increased clinical costs and material and development costs.
|
| • |
Net loss was $8,187,810, or ($1.59) per basic and diluted share attributable to common stockholders, for the nine months ended September 30, 2026, compared to a net loss of $14,677,582, or ($9.25) per basic and diluted share attributable
to common stockholders, for the nine months ended September 30, 2025.
|
| • |
Cash and cash equivalents as of September 30, 2026, were approximately $23.9 million and the Company had an accumulated deficit of approximately $154.0 million.
|
|
Assets
|
September 30, 2026
|
December 31,
2025
|
||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
23,913,946
|
9,266,353
|
|||||
|
Accounts receivable, net
|
233,778
|
616,600
|
||||||
|
Inventory
|
6,166,371
|
5,740,249
|
||||||
|
Prepaid and other current assets
|
893,098
|
833,133
|
||||||
|
Total current assets
|
31,207,193
|
16,456,335
|
||||||
|
Property and equipment, at cost:
|
||||||||
|
Leasehold improvements
|
1,238,886
|
1,238,886
|
||||||
|
Office equipment
|
91,610
|
78,155
|
||||||
|
Furniture and fixtures
|
424,586
|
417,876
|
||||||
|
Machinery and equipment
|
3,125,855
|
3,065,713
|
||||||
|
Construction in progress
|
991,124
|
897,885
|
||||||
|
5,872,061
|
5,698,515
|
|||||||
|
Less accumulated depreciation
|
(3,991,222
|
)
|
(3,802,940
|
)
|
||||
|
Net property and equipment
|
1,880,839
|
1,895,575
|
||||||
|
Long-term assets:
|
||||||||
|
Lease right-of-use assets, net
|
952,796
|
1,297,121
|
||||||
|
Intangible assets, net of accumulated amortization
|
99,902
|
134,914
|
||||||
|
Other long-term assets
|
946,928
|
940,232
|
||||||
|
Total long-term assets
|
1,999,626
|
2,372,267
|
||||||
|
Total assets
|
$
|
35,087,658
|
20,724,177
|
|||||
|
Liabilities and Stockholders’ Equity
|
September 30, 2026
|
December 31, 2025
|
||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
$1,958,546
|
1,830,124
|
|||||
|
Accrued expenses
|
855,377
|
1,265,773
|
||||||
|
Note payable
|
292,229
|
—
|
||||||
|
Clinical holdback – current portion
|
29,250
|
52,644
|
||||||
|
Operating lease liabilities – current portion
|
465,960
|
487,624
|
||||||
|
Total current liabilities
|
3,601,362
|
3,636,165
|
||||||
|
Long-term liabilities:
|
||||||||
|
Clinical holdback – long-term portion
|
58,179
|
52,370
|
||||||
|
Convertible notes payable, net
|
3,717,653
|
3,178,864
|
||||||
|
Conversion option liability
|
—
|
2,014,000
|
||||||
|
Warrants liabilities
|
—
|
4,943,000
|
||||||
|
Operating lease liabilities – long-term portion
|
682,302
|
1,030,476
|
||||||
|
Total long-term liabilities
|
4,458,134
|
11,218,710
|
||||||
|
Total liabilities
|
8,059,496
|
14,854,875
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity:
|
||||||||
|
Common stock, $0.001 par, 200,000,000 shares authorized, 8,662,139 shares issued and 8,656,277 shares outstanding as of September 30, 2026; and
2,986,116 shares issued and 2,980,254 shares outstanding as of December 31, 2025
|
||||||||
|
8,662
|
2,986
|
|||||||
|
Treasury stock, 5,862 common shares
|
(60,000
|
)
|
(60,000
|
)
|
||||
|
Warrants
|
19,023,695
|
5,246,150
|
||||||
|
Additional paid-in capital
|
162,069,759
|
146,506,310
|
||||||
|
Accumulated deficit
|
(154,013,954
|
)
|
(145,826,144
|
)
|
||||
|
Total stockholders’ equity
|
27,028,162
|
5,869,302
|
||||||
|
|
||||||||
|
Total liabilities and stockholders' equity
|
$
|
35,087,658
|
20,724,177
|
|||||
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
|
2026
|
2025
|
2026
|
2025
|
|||||||||||||
|
Sales
|
$
|
404,597
|
729,394
|
1,161,313
|
1,479,926
|
|||||||||||
|
Cost of sales (excluding depreciation expense)
|
187,496
|
293,838
|
488,538
|
569,275
|
||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Research and development
|
1,942,927
|
1,382,022
|
5,199,206
|
5,764,923
|
||||||||||||
|
Sales and marketing
|
943,002
|
1,143,805
|
3,552,755
|
3,037,349
|
||||||||||||
|
General and administrative
|
1,704,091
|
1,477,800
|
5,418,059
|
4,817,485
|
||||||||||||
|
Depreciation and amortization
|
77,091
|
85,697
|
242,172
|
256,835
|
||||||||||||
|
Total operating expenses
|
4,667,111
|
4,089,324
|
14,412,192
|
13,876,592
|
||||||||||||
|
Loss from operations
|
(4,450,010
|
)
|
(3,653,768
|
)
|
(13,739,417
|
)
|
(12,965,941
|
)
|
||||||||
|
Other income (expense):
|
||||||||||||||||
|
Interest income
|
85,610
|
17,315
|
155,131
|
53,488
|
||||||||||||
|
Change in fair value of Conversion Option liability
|
—
|
—
|
1,732,413
|
—
|
||||||||||||
|
Change in fair value of Warrants liabilities
|
—
|
—
|
4,228,000
|
—
|
||||||||||||
|
Interest expense
|
(200,415
|
)
|
(532,073
|
)
|
(563,072
|
)
|
(1,483,022
|
)
|
||||||||
|
Other expense
|
—
|
(26,295
|
)
|
—
|
(286,295
|
)
|
||||||||||
|
Total other income (expense), net
|
(114,805
|
)
|
(541,053
|
)
|
5,552,472
|
(1,715,829
|
)
|
|||||||||
|
Loss before income taxes
|
(4,564,815
|
)
|
(4,194,821
|
)
|
(8,186,945
|
)
|
(14,681,770
|
)
|
||||||||
|
Income tax expense (benefit)
|
—
|
—
|
865
|
(4,188
|
)
|
|||||||||||
|
Net loss
|
$
|
(4,564,815
|
)
|
(4,194,821
|
)
|
(8,187,810
|
)
|
(14,677,582
|
)
|
|||||||
|
Net loss attributable to common stockholders
|
$
|
(4,564,815
|
)
|
(4,194,821
|
)
|
(8,187,810
|
)
|
(14,677,582
|
)
|
|||||||
|
Basic and diluted loss per share
|
$
|
(0.53
|
)
|
(2.05
|
)
|
(1.59
|
)
|
(9.25
|
)
|
|||||||
|
Weighted-average common shares and pre-funded warrants outstanding, basic and diluted
|
8,660,381
|
2,050,761
|
5,136,109
|
1,586,992
|
||||||||||||